Skip to main content
main-content

01.12.2012 | Research | Ausgabe 1/2012 Open Access

World Journal of Surgical Oncology 1/2012

Clinical significance of clusterin expression in pancreatic adenocarcinoma

Zeitschrift:
World Journal of Surgical Oncology > Ausgabe 1/2012
Autoren:
Junshuo Jin, Joon-Mee Kim, Yoon-Seok Hur, Won Pyo Cho, Keon-Young Lee, Seung-Ik Ahn, Kee Chun Hong, In-Sun Park
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7819-10-146) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

All authors read and approved the final manuscript. JJ carried out the molecular studies. JMK interpreted the pathologic findings. YSH performed the operations. WPC carried out the data collection. KYL performed the operations and drafted the manuscript. SIA performed the operations. KCH performed the operations. ISP directed and interpreted the immunohistochemical stain.

Abstract

Background

Clusterin is known to be expressed in many human neoplasms, and is believed to participate in the regeneration, migration, and anti-apoptosis of tumor cells. However, few reports have addressed the relationship between the manifestation of clusterin and clinicopathologic parameters in pancreas cancer patients. In the present study, the authors investigated the expression of clusterin and its clinical significance in pancreatic adenocarcinoma.

Methods

Immunohistochemical staining was performed for clusterin in tumor tissues obtained from patients who received pancreatic resection with radical intent, and the associations of clusterin expression with various clinicopathologic parameters were analyzed in addition to the relation between its expression and survival.

Results

Immunoreactivity for clusterin was observed in 17 of the 52 (33%) pancreatic adenocarcinomas examined. In addition, clusterin positivity was found to be associated with preoperative serum carcinoembryonic antigen level, perineural invasion, and, most strongly, lymph node metastasis. The survival analysis identified tumor differentiation and lymph node metastasis as the only significant prognostic factors.

Conclusion

Although not an independent prognostic factor, clusterin immunoreactivity can be used in conjunction with lymph node metastasis to predict survival in cases of pancreatic adenocarcinoma.
Zusatzmaterial
Authors’ original file for figure 1
12957_2011_1028_MOESM1_ESM.jpeg
Authors’ original file for figure 2
12957_2011_1028_MOESM2_ESM.jpeg
Authors’ original file for figure 3
12957_2011_1028_MOESM3_ESM.jpeg
Authors’ original file for figure 4
12957_2011_1028_MOESM4_ESM.jpeg
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

World Journal of Surgical Oncology 1/2012 Zur Ausgabe

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise